Format

Send to

Choose Destination
Oncogene. 2018 Aug;37(32):4372-4384. doi: 10.1038/s41388-018-0257-5. Epub 2018 May 10.

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.

Author information

1
Department of Molecular Medicine, The Scripps Research Institute, Florida, USA.
2
Amgen Inc., Thousand Oaks, CA, USA.
3
Department of Molecular Medicine, The Scripps Research Institute, Florida, USA. jkissil@scripps.edu.
4
Department of Molecular Medicine, The Scripps Research Institute, Florida, USA. spicert@scripps.edu.

Abstract

The RAS proteins are the most frequently mutated oncogenes in cancer, with highest frequency found in pancreatic, lung, and colon tumors. Moreover, the activity of RAS is required for the proliferation and/or survival of these tumor cells and thus represents a high-value target for therapeutic development. Direct targeting of RAS has proven challenging for multiple reasons stemming from the biology of the protein, the complexity of downstream effector pathways and upstream regulatory networks. Thus, significant efforts have been directed at identifying downstream targets on which RAS is dependent. These efforts have proven challenging, in part due to confounding factors such as reliance on two-dimensional adherent monolayer cell cultures that inadequately recapitulate the physiologic context to which cells are exposed in vivo. To overcome these issues, we implemented a high-throughput screening (HTS) approach using a spheroid-based 3-dimensional culture format, thought to more closely reflect conditions experienced by cells in vivo. Using isogenic cell pairs, differing in the status of KRAS, we identified Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRasG12V allele. Significantly, the identification of Proscillaridin A was facilitated by the 3D screening platform and would not have been discovered employing standard 2D culturing methods.

PMID:
29743592
PMCID:
PMC6138545
DOI:
10.1038/s41388-018-0257-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center